Site navigation

High Profile Appointments to Support Growth at Cumulus Oncology

Ross Kelly


Cumulus Oncology

Four senior figures from the biopharmaceutical industry will support the company’s future growth ambition.

Drug discovery accelerator Cumulus Oncology has unveiled the appointment of four senior figures to its advisory board as the company embarks on a new stage of growth.

Mohamed ‘Raz’ Dewji, Chris Brinsmead CBE, Ian Waddell and Nicola Broughton will join Cumulus and advise on further asset class acquisition and investment.

The four will take executive, strategic or advisory roles in the spin-out companies created as part of the Cumulus business model.

Founded in 2017 by Dr Clare Wareing, Cumulus Oncology creates and manages spin-out companies which specialise in the development of anti-cancer treatments.

The new appointments come amid an exciting period for the Edinburgh-headquartered firm. In July this year, the organisation secured £1.7 million following an investment round led by St Andrews-based Eos Advisory.

Additionally, in September Cumulus became a key founder of Modulus Oncology, a biotech startup spun out of the University of Sheffield.

Commenting on the announcement, Wareing said: “We are continuing to scale the business and are excited to have attracted the support of so many highly regarded figures in big pharma and biotech.”

Raz Dewji brings over 30 years of experience in the sector, having contributed to six oncology drug approvals and launches in senior roles with Pfizer, GSK, Novartis and AstraZeneca.

Nicola Broughton, co-founder and managing partner at Oskare Capital and a former Principal at Mercia Asset Management PLC, is an experienced life sciences investor, executive and non-executive director with strong expertise in identifying and nurturing university spin-outs.

Alan Wise, Chairman and Co-Founder at Cumulus, commented: “The skill set the advisors bring will help focus the company’s growth and aspirations in the oncology drug discovery sectors in universities, biotech companies and drug discovery organisations.

“Their proven expertise will enhance our ability to shortlist oncology assets for future spin-out opportunities and create value-adding deal structures around these opportunities.”


Chris Brinsmead CBE is a council member at Imperial College and former adviser to the UK government on life sciences. Previously, Brinsmead held leadership roles at ICI and AstraZeneca.

Ian Waddell is a former Director of Discovery Medicine at AstraZeneca, Head of Biology at Cancer Research UK and in 2017 joined Charles River Laboratories where he is now Chief Science Officer for Early Discovery.

Wareing added: “In Raz, Chris, Ian and Nicola, we have some of the UK’s leading figures in oncology drug development and commercialisation. Getting them on board furthers the global aspirations we have for Cumulus.”

Ross Kelly

Staff Writer

Latest News

Editor's Picks Recruitment
Infrastructure Trending Articles
Editor's Picks Social Media
Business Editor's Picks
%d bloggers like this: